Advancing Patient Care: Nanoform and Aprecia Pioneer 3D Printed Nanomedicines for Enhanced Drug Delivery

In a significant step towards revolutionizing pharmaceutical development and patient care, Nanoform, a leader in innovative nanoparticle medicine, and Aprecia, a pioneering 3D printing pharmaceutical company, have announced a strategic collaboration. This powerful partnership aims to accelerate the advancement of 3D printed nanomedicines. By skillfully combining their respective cutting-edge technologies, the companies seek to leverage unique synergies in the realm of nanoparticle-enabled 3D printed dosage forms. The ultimate goal is to discover and implement novel solutions for patient-centric therapies, offering substantial benefits to both patients and the broader pharmaceutical industry.

The collaboration between Nanoform and Aprecia represents a natural alignment of expertise, promising to reshape how medications are manufactured and delivered. Their complementary technologies position them perfectly to address some of the most persistent challenges in drug formulation. Chris Gilmore, CEO of Aprecia, emphasized the transformative potential of this alliance, stating:

“Aprecia’s proprietary 3DP technology platforms are focused on providing solutions to our partner’s toughest formulation challenges that can’t be achieved through conventional manufacturing technologies. The opportunity to join forces with Nanoform will enable new fast-acting and high-performance buccal and oral dosage forms not previously seen in the industry.”

This sentiment underscores the innovative spirit driving both organizations and their shared vision for a future where drug delivery is more efficient, precise, and tailored to individual patient needs.

This partnership is particularly impactful given the specialized strengths each company brings to the table. Aprecia holds a distinguished reputation within the pharmaceutical sector, notably for achieving the first and only FDA-approved three-dimensionally-printed pharmaceutical product approval in 2015. Their groundbreaking ZipDose technology has redefined possibilities in oral drug delivery, enabling rapidly disintegrating dosage forms that can significantly improve patient compliance and therapeutic onset. This technology allows for the creation of porous structures that dissolve almost instantly upon contact with moisture, making it ideal for patients who struggle with swallowing traditional pills.

On the other hand, Nanoform is dedicated to overcoming critical hurdles in drug development, primarily by reducing clinical attrition and enhancing the performance of drug molecules through its proprietary nanoforming technologies and advanced formulation services. Nanoform’s innovative approach focuses on creating drug nanoparticles that exhibit increased surface area, leading to faster dissolution rates and improved bioavailability. This capability is crucial for drugs that typically have poor solubility, allowing for lower doses and more effective treatments. By ‘nanoforming’ active pharmaceutical ingredients (APIs), Nanoform can significantly improve a drug’s absorption profile, making it more potent and predictable.

The initial phase of their collaboration will strategically combine Nanoform’s fast-dissolution nanoformed particles with Aprecia’s renowned ZipDose technology for rapid disintegration. This powerful fusion is designed to enable high-performance buccal and oral delivery of medicines, particularly for patients where rapid absorption is absolutely essential. Imagine a scenario where a critical medication needs to take effect almost immediately; the combination of rapidly dissolving nanoparticles within a rapidly disintegrating 3D printed matrix provides an unprecedented solution. This synergy not only addresses solubility challenges but also creates a delivery system that is highly efficient and patient-friendly.

Beyond immediate therapeutic effects, Aprecia and Nanoform are deeply committed to developing patient-centric advancements that improve overall treatment experience. This includes creating products with lower dosages, reduced excipient content, and a diminished pill burden. Lower dosages mean fewer active ingredients are needed, potentially leading to fewer side effects and lower production costs. Reduced excipient content translates to a purer drug product, which can be crucial for patients with sensitivities or allergies to inactive ingredients. Furthermore, decreasing the “pill burden” – the number of pills a patient has to take – significantly enhances adherence, especially for individuals with chronic conditions requiring multiple medications. These considerations highlight a holistic approach to patient care, moving beyond just efficacy to encompass comfort and ease of use.

Professor Edward Hæggström, CEO of Nanoform, passionately articulated this patient-focused philosophy:

“At the heart of everything we do is the patient. This is a fantastic opportunity to demonstrate the power of small for rapid drug absorption, potentially bypassing the first-pass metabolism via a novel dosage form such as buccal delivery with Aprecia’s 3DP technology platforms. We look forward to this exciting collaboration and to supporting our pharmaceutical partners with this unique offering for fast-acting and quick-dissolving nanomedicines.”

His statement underscores the critical advantage of rapid absorption, particularly through buccal delivery, which allows drugs to enter the bloodstream directly, thereby bypassing the liver’s first-pass metabolism. This mechanism can prevent drug degradation and increase drug bioavailability, making treatments more effective and allowing for even lower dosages. The ability to circumvent first-pass metabolism is a game-changer for many orally administered drugs that suffer from extensive breakdown in the liver, often requiring higher doses or alternative delivery routes.

The potential applications of this combined technology extend far beyond simple convenience. For patients requiring immediate relief from acute symptoms, or those with conditions that impair swallowing, these 3D printed nanomedicines could be life-changing. Moreover, this approach opens doors for personalized medicine, where dosages and drug release profiles could be precisely tailored for individual patients, optimizing therapeutic outcomes and minimizing adverse effects. The integration of nanotechnology with 3D printing offers an unprecedented level of control over drug formulation, allowing for complex geometries and intricate internal structures that are impossible to achieve with traditional manufacturing techniques. This precision enables the development of smart drug delivery systems that can release active ingredients in a controlled, sustained, or pulsed manner, further enhancing patient benefits.

This pioneering collaboration between Nanoform and Aprecia marks a pivotal moment in the evolution of pharmaceutical science. By synergizing their core competencies, they are not only addressing existing challenges in drug delivery but are also forging a path toward a future where medicines are more effective, safer, and inherently designed with the patient at the forefront. The pharmaceutical industry is constantly seeking innovative methods to improve drug efficacy and patient experience, and this partnership exemplifies the cutting edge of such efforts. Their combined expertise promises to unlock new therapeutic avenues, redefine treatment paradigms, and ultimately enhance the quality of life for countless individuals worldwide.

For those interested in delving deeper into this exciting development, the full press release is available HERE. We invite your thoughts and perspectives on Nanoform and Aprecia’s transformative collaboration. Share your insights in a comment below or engage with us on our social media platforms: Facebook,Twitter, andLinkedIn pages! Don’t miss out on the latest advancements in 3D printing; sign up for our free weeklyNewsletter here, delivering the most current 3D printing news straight to your inbox!

*Cover picture credit: Nanoform